Daclatasvir/Asunaprevir/Beclabuvir regulates innate immunity by inhibition of nonstructural 5B and suppresses liver fibrosis development

Daclatasvir/Asunaprevir/Beclabuvir regulates innate immunity by inhibition of nonstructural 5B and suppresses liver fibrosis development - Daclatasvir/Asunaprevir/Beclabuvir regulates innate immunity by inhibition of nonstructural 5B and suppresses liver fibrosis development

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026917

Enrollment

Registered

2017-05-01

Start date

2017-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients with HCV genotype1 which are categorized as F2, F3 or F4 by New Inuyama Classification

Exclusion criteria

Exclusion criteria: 1. With other concomitant chronic liver diseases including Heptitis B, Autoimmune hepatitis, Primary biliary cholangitis, Primary sclerosing cholangitis, Alcoholic steatohepatitis, Nonalcoholic steatohepatitis, Hemochromatosis or Wilson's disease. 2. With decompensated cirrhosis 3. With cancers, severe cardiopulmonary or renal diseases or inflammatory bowel diseases. 4. With previous history of gastrectomy, enterectomy or liver transplantation. 5. With treatment of immunosuppressants, antibiotics, probiotics, proton pump inhibitors or H2 blockers.

Design outcomes

Primary

Measure	Time frame
Pathological change in liver fibrosis in the patients with between pretreatment and 36 weeks after therapeutic intervention	—

Secondary

Measure	Time frame
Change in serum fibrogenic markers and gu microbiome in the patients with between pretreatment and 36 weeks after therapeutic intervention	—

Countries

Japan

Contacts

Public ContactKosuke Kaji

Nara Medical University Third Department of Internal Medicine

kajik@naramed-u.ac.jp0744-22-3051(ext.3415)

Outcome results